cimetidine has been researched along with Soft Tissue Neoplasms in 4 studies
Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.
cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.
Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted parallel phase II trials of cimetidine as a single agent and the combination N-phosphonacetyl-L-aspartate (PALA) plus L-alanosine among 40 previously untreated patients with biopsy-proven, measurable disseminated malignant melanoma." | 9.06 | Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma. ( Chang, M; Creagan, ET; Cullinan, SA; Ebbert, L; Mailliard, JA; Morton, RF; Veeder, MH, 1987) |
| "We conducted parallel phase II trials of cimetidine as a single agent and the combination N-phosphonacetyl-L-aspartate (PALA) plus L-alanosine among 40 previously untreated patients with biopsy-proven, measurable disseminated malignant melanoma." | 5.06 | Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma. ( Chang, M; Creagan, ET; Cullinan, SA; Ebbert, L; Mailliard, JA; Morton, RF; Veeder, MH, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (75.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gold, JE | 1 |
| Malamud, SC | 1 |
| LaRosa, F | 1 |
| Osband, ME | 1 |
| Creagan, ET | 2 |
| Ahmann, DL | 1 |
| Frytak, S | 1 |
| Long, HJ | 1 |
| Chang, MN | 1 |
| Itri, LM | 1 |
| Armitage, JO | 1 |
| Sidner, RD | 1 |
| Morton, RF | 1 |
| Cullinan, SA | 1 |
| Mailliard, JA | 1 |
| Ebbert, L | 1 |
| Veeder, MH | 1 |
| Chang, M | 1 |
2 trials available for cimetidine and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses.
Topics: Adjuvants, Immunologic; Antibodies; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Prot | 1987 |
Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma.
Topics: Alanine; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cimetidine; Drug Evaluation; | 1987 |
2 other studies available for cimetidine and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Adoptive chemoimmunotherapy using ex vivo activated memory T-cells and cyclophosphamide: tumor lysis syndrome of a metastatic soft tissue sarcoma.
Topics: Aged; Cimetidine; Clinical Protocols; Cyclophosphamide; Humans; Immunologic Memory; Immunotherapy, A | 1993 |
Antitumour effect of cimetidine.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma; Carcinoma, Bronchogenic; Cimetidine; Female | 1979 |